Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H27F4N3O3S |
Molecular Weight | 525.559 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)S(C)(=O)=O)C(F)(F)F)C(=O)NC3(CC3)C#N
InChI
InChIKey=FWIVDMJALNEADT-SFTDATJTSA-N
InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1
DescriptionSources: http://adisinsight.springer.com/drugs/800024552Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18226527 | https://www.ncbi.nlm.nih.gov/pubmed/27681784
Sources: http://adisinsight.springer.com/drugs/800024552
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18226527 | https://www.ncbi.nlm.nih.gov/pubmed/27681784
Odanacatib is a potent, selective, and neutral cathepsin K inhibitor, an enzyme involved in bone resorption. Merck & Co was developing odanacatib, a once-weekly, oral Odanacatib, for the treatment of postmenopausal osteoporosis and osteoporosis in men. Merck & Co. has discontinued development of its cathepsin K inhibitor odanacatib, citing an increased risk of cardiovascular events for the osteoporosis drug.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL268 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18226527 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
839.2 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
154.7 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
477.3 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.76 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
2.23 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
-0.01 mg single, oral dose: -0.01 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
353.5 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
56.2 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27402726 |
1 mg single, intravenous dose: 1 mg route of administration: Intravenous experiment type: SINGLE co-administered: ODANACATIB |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
1.82 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16.1 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
3.2 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
9.4 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.73 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
2.11 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
-0.01 mg single, oral dose: -0.01 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
6.4 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.7 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27402726 |
1 mg single, intravenous dose: 1 mg route of administration: Intravenous experiment type: SINGLE co-administered: ODANACATIB |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
1.87 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
62.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
59.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
48.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
104.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27402726 |
1 mg single, intravenous dose: 1 mg route of administration: Intravenous experiment type: SINGLE co-administered: ODANACATIB |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
50.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23013236 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODANACATIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg 1 times / week multiple, oral (unknown) Studied dose Dose: 50 mg, 1 times / week Route: oral Route: multiple Dose: 50 mg, 1 times / week Sources: |
unhealthy, ADULT n = 146 Health Status: unhealthy Condition: osteoporosis Age Group: ADULT Sex: M Food Status: UNKNOWN Population Size: 146 Sources: |
Disc. AE: Myalgia... AEs leading to discontinuation/dose reduction: Myalgia (0.7%) Sources: |
300 mg 1 times / day multiple, oral (starting) Highest recorded dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
healthy n = 56 Health Status: healthy Sex: M+F Food Status: FASTED Population Size: 56 Sources: |
Other AEs: Abdominal pain, Application-site erosion... Other AEs: Abdominal pain (5.4%) Sources: Application-site erosion (5.4%) Application-site erythema (17.9%) Pruritus (7.1%) |
50 mg 1 times / week multiple, oral (unknown) Studied dose Dose: 50 mg, 1 times / week Route: oral Route: multiple Dose: 50 mg, 1 times / week Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: low bone mineral density Sex: F Food Status: UNKNOWN Population Size: 28 Sources: |
Disc. AE: Basal cell carcinoma... AEs leading to discontinuation/dose reduction: Basal cell carcinoma (3.6%) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Myalgia | 0.7% Disc. AE |
50 mg 1 times / week multiple, oral (unknown) Studied dose Dose: 50 mg, 1 times / week Route: oral Route: multiple Dose: 50 mg, 1 times / week Sources: |
unhealthy, ADULT n = 146 Health Status: unhealthy Condition: osteoporosis Age Group: ADULT Sex: M Food Status: UNKNOWN Population Size: 146 Sources: |
Application-site erythema | 17.9% | 300 mg 1 times / day multiple, oral (starting) Highest recorded dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
healthy n = 56 Health Status: healthy Sex: M+F Food Status: FASTED Population Size: 56 Sources: |
Abdominal pain | 5.4% | 300 mg 1 times / day multiple, oral (starting) Highest recorded dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
healthy n = 56 Health Status: healthy Sex: M+F Food Status: FASTED Population Size: 56 Sources: |
Application-site erosion | 5.4% | 300 mg 1 times / day multiple, oral (starting) Highest recorded dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
healthy n = 56 Health Status: healthy Sex: M+F Food Status: FASTED Population Size: 56 Sources: |
Pruritus | 7.1% | 300 mg 1 times / day multiple, oral (starting) Highest recorded dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
healthy n = 56 Health Status: healthy Sex: M+F Food Status: FASTED Population Size: 56 Sources: |
Basal cell carcinoma | 3.6% Disc. AE |
50 mg 1 times / week multiple, oral (unknown) Studied dose Dose: 50 mg, 1 times / week Route: oral Route: multiple Dose: 50 mg, 1 times / week Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: low bone mineral density Sex: F Food Status: UNKNOWN Population Size: 28 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | yes (co-administration study) Comment: Coadministration did not affect R( )- and S(-)-warfarin exposure. Sources: https://pubmed.ncbi.nlm.nih.gov/24142206/ |
|||
no | yes (co-administration study) Comment: Coadministration did not affect R( )- and S(-)-warfarin exposure. Sources: https://pubmed.ncbi.nlm.nih.gov/24142206/ |
|||
no | yes (co-administration study) Comment: Coadministration did not affect R( )- and S(-)-warfarin exposure. Sources: https://pubmed.ncbi.nlm.nih.gov/24142206/ |
|||
no | yes (co-administration study) Comment: Coadministration did not affect R( )- and S(-)-warfarin exposure. Sources: https://pubmed.ncbi.nlm.nih.gov/24142206/ |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
minor | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: http://adisinsight.springer.com/drugs/800024552
Merck is conducting a long-term phase II trial that is assessing four different doses of odanacatib (3mg, 10mg, 25mg and 50mg once-weekly for 2 years) in women with postmenopausal osteoporosis (NCT00112437; EudraCT2005-001511-22). Results from this phase IIb study showed that odanacatib 50mg increased bone mineral density (BMD) from baseline, and was generally safe and well tolerated.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25394885
1 nM odanacatib had suppressive effects on the expression levels of inflammatory cytokines in murine RAW 264.7 cells were cultured in the presence of the receptor activator of NF-kB and lipopolysaccharide
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67439
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
||
|
NCI_THESAURUS |
C783
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8962
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
PRIMARY | |||
|
100000128030
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
PRIMARY | |||
|
ODANACATIB
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
PRIMARY | |||
|
DB06670
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
PRIMARY | |||
|
603139-19-1
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
PRIMARY | |||
|
C66981
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
PRIMARY | |||
|
TT-63
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
PRIMARY | |||
|
DTXSID40209075
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
PRIMARY | |||
|
N673F6W2VH
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
PRIMARY | |||
|
CHEMBL481611
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
PRIMARY | |||
|
C527128
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
PRIMARY | |||
|
m8131
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
10152654
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
PRIMARY | |||
|
SUB34600
Created by
admin on Fri Dec 15 16:06:13 GMT 2023 , Edited by admin on Fri Dec 15 16:06:13 GMT 2023
|
PRIMARY |
ACTIVE MOIETY